English Journal

Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma.

Kobayashi H, Tanaka Y, Yagi J, Minato N, Tanabe K.SourceDepartment of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan. hirohitokobayashi-jua@umin.ac.jp
Cancer immunology, immunotherapy : CII.Cancer Immunol Immunother.2011 Aug;60(8):1075-84. doi: 10.1007/s00262-011-1021-7. Epub 2011 Apr 26.
Human Vγ2 Vδ2-bearing T cells have recently received much attention in cancer immunotherapy. In this study, we conducted a phase I/II clinical trial of the adoptive transfer of γδ T cells to patients with advanced renal cell carcinoma. Eleven patients who had undergone nephrectomy and had lung
PMID 21519826

Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study.

Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, Minato N, Toma H.SourceDepartment of Urology, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan. hirohitokobayashi-jua@umin.ac.jp
Cancer immunology, immunotherapy : CII.Cancer Immunol Immunother.2007 Apr;56(4):469-76. Epub 2006 Jul 19.
PURPOSE: Although various types of immunotherapy have been used to improve the prognosis of patients with advanced renal cell carcinoma (RCC), adoptive immunotherapy using gamma-delta (gammadelta) T cells has not yet been tried. In this study, we designed a pilot study of adoptive immunotherapy usin
PMID 16850345

Modulation of immune parameters in patients with metastatic renal-cell cancer receiving combination immunotherapy (IL-2, IFN alpha and autologous IL-2-activated lymphocytes).

Gratama JW, Schmitz PI, Goey SH, Lamers CH, Stoter G, Bolhuis RL.SourceDepartment of Clinical and Tumor Immunology, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.
International journal of cancer. Journal international du cancer.Int J Cancer.1996 Jan 17;65(2):152-60.
We treated 72 patients with metastatic renal-cell cancer according to 2 protocols consisting of two 5-week induction cycles of continuous i.v. high-dose interleukin-2 (IL-2), i.m. interferon-alpha (IFN alpha) and ex vivo IL-2-activated lymphocytes, followed for patients with stable disease (SD), par
PMID 8567110

Japanese Journal

宮本牧,高森幹雄,村田研吾,和田暁彦,藤田明
肺癌 50(2), 186-193, 2010
… 受診，両肺に多発結節影を指摘された．CTで両肺，肝臓，左腸骨，右心房に腫瘤性病変を認めた．左腸骨のCTガイド下生検と右歯肉腫瘤の生検組織より血管肉腫と診断した．化学療法（docetaxel），免疫療法（teceleukin），局所放射線治療を行ったが，入院80日目に肺出血による呼吸不全のため死亡した．病理解剖では右心房原発低分化型血管肉腫を確認した．結論．過去の報告例も含め肺転移を起こしてからの予後は，平 …
NAID 130000252355

小原宏之,林大海,森弘樹,梅田整,秦維郎
Skin cancer : official organ of the Japanese Society for Skin Cancer = 皮膚悪性腫瘍研究会機関誌 15(3), 280-283, 2000-12-25
… So we continued rIL-2 therapy with teceleukin by one shot arterial injection. … We suspected drug eruptions which were caused by teceleukin.Erythema is well known as one of the side effects of rIL-2. …
NAID 10025716421